Compare Consolidated Edison, Inc. (ED) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Illumina, Inc. — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $38.70B), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Consolidated Edison, Inc. and Illumina, Inc. are close in size by market cap, and Consolidated Edison, Inc. pays a 3.36% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Illumina, Inc. for 83 Days on average.
| ED | ILMN | |
|---|---|---|
Market Cap | $38.70B | $40.43B |
Volume | 2,154,810 | 2,948,626 |
Sector | Utilities | Health |
52-Week High | $115.46 | $293.69 |
52-Week Low | $95.37 | $91.00 |
Typical Hold Time | 75 Days | 83 Days |
Enterprise Value | $65.55B | $41.79B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ED (Consolidated Edison) trades at $105.99, up 0.83% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue grew to $16.92B with a net income margin of 12.53%, while recent earnings have been mixed with a Q1 2026 miss. The company maintains a solid dividend, with a recent $0.89 payout announced for September 2026, and is highlighted in news for its economic impact in New York and involvement in electric bus infrastructure.
Outlook is balanced; ED offers stability as a utility stock with consistent dividends and moderate growth, but faces risks from debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings. Key catalysts include the upcoming investor presentation on October 6, 2026, and execution on capital investments. Risks involve regulatory changes and economic sensitivity.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
